Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yang Liang

Showing results (291-300 of 293) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 293 results.
Cell Reports. Medicine|February 22, 2023
Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphomaXiao-Peng Tian, Yu-Chen Zhang, Ning-Jing Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving ChemotherapyYun Wang, Yan-Yu Cai, Tobias Herold, et al.
BMC Cancer|October 14, 2023
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trialZhongjun Xia, Yun Leng, Baijun Fang, et al.
Pageof 30

Showing results (291-300 of 293) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 293 results.
Cell Reports. Medicine|February 22, 2023
Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphomaXiao-Peng Tian, Yu-Chen Zhang, Ning-Jing Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving ChemotherapyYun Wang, Yan-Yu Cai, Tobias Herold, et al.
BMC Cancer|October 14, 2023
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trialZhongjun Xia, Yun Leng, Baijun Fang, et al.
Pageof 30